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PROTEIN AND URIC ACID PATTERNS IN MALIGNANT DISEASE 
I INTRODUCTION 
In an earlier, detailed study of 92 patients suffering 
from malignant disease and all receiving cytotoxic drugs,a number 
of interesting facts emerged. 
Of these, two were considered of particular interest. 
It was noted that in 60`, of the total cases the o< -2- globulin 
fraction of the serum electrophoretic pattern was raised, often 
to a considerable degree. If the cases of locally advanced 
disease or those demonstrating metastases were alone considered, 
then the percentage showing a raised 0C-2-globulin fraction was 76. 
Secondly, it was found that the serum and urinary uric acid levels 
were frequently raised in malignant disease and could be further 
altered by treatment with cytotoxic drugs or radiotherapy. 
During this original study I further became impressed by the 
lack of an objective means of determining tumour response to 
cytotoxins (or radiotherapy) at an early stage in the treatment. 
The significance of these changes in the protein pattern and 
in the uric acid levels in plasma and urine is obscure and 
relatively scant attention has been given to these problems in 
clinical publications. 
It/ 
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It was known that changes occur in the globulin fraction 
of the plasma proteins in certain liver diseases. .G élhorn, 
in 1958, reported a greater agglutination of leucocytes of 
cancer patients than of those of normal patients by an antiserum 
prepared against thee( -2 fraction of the serum No report, 
however, was made of the actual levels of o(-2- globulin found in 
the serum of these patients. 
In 37 cases of metastatic carcinomatosis Sunderman (1964) 
demonstrated a significant increase in the mean concentrations 
of c(-1 and O&-2 globulins in the electrophoretic fractions of 
the serum proteins He was of the opinion that these increases 
constituted a common and non -specific pattern which should not 
be regarded as evidence of neoplastic disease. No attempt was 
made to determine the significance of these findings, but the 
comment was made that these changes "might be of value in 
determining remissions ". 
Although a slightly different problem, it is of interest 
to note that Macbeth and his co- workers in Edmonton were able to 
demonstrate an elevation of the carbohydrate fraction of the 
plasma glycoproteins in patients and experimental animals 
harbouring malignant neoplasms. They commented that this 
elevation was not specific for malignant disease but was intimately 
related to the neoplastic process. They further drew attention 




It thus appears that, although a very considerable amount of 
work is in progress on such problems as the ultrastructure of 
malignant cells, the various aspects of nucleic acid synthesis 
and metabolism, and on the problem of immunity in malignancy, 
relatively little work has been done, at a clinical level, on the 
significance and potential value of the changing patterns of 
O( -2- globulin in malignant disease. 
Even less information is available on the changes which 
occur in uric acid levels in plasma and urine in malignancy, 
particularly after treatment with cytotoxic drugs. It was known 
that hyperuricaemia could be produced by radiotherapy, steroids, 
or cytotoxic drugs in leukaemia and reticulosis, and that on 
occasion hyperuricaemia may be sufficiently severe to cause acute 
renal failure: The employment of serial uric acid determinations 
in plasma and urine as a means of assessing response to cytotoxic 
treatment of solid tumours has, however, not been reported. 
It was therefore considered that by a detailed study of the 
changes in serum electrophoretic pattern, with particular reference 
to the 2- globulin fraction, together with a simultaneous study of 
the changes in plasma and urinary uric acid levels before and after 
treatment with cytotoxic drugs, some diagnostic and prognostic 
significance might derive from the results obtained. 
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II AIMS 
The aims of the study may therefore be summarised as 
follows:- 
(a) To obtain support for the concept that the 04-2- globulin 
fraction of the serum electrophoretic pattern is frequently raised 
in malignant disease and may be of some diagnostic significance. 
(b) To study the changes in the serum 0( -2- globulin and in 
the uric acid levels in plasma and urine before and after 
administration of cytotoxic drugs in order to obtain information 
of possible prognostic significance. 
III METHOD 
It was considered feasible to carry out the two parts of the 
study simultaneously. The total study was, however, planned in 
three phases. 
Phase 1.- The study of a selected group of patients 
demonstrating advanced malignant disease and treated with cytotoxic 
drugs. This group of patients to be controlled against patients 
suffering from advanced inflammatory disease requiring operative 
treatment. 
Phase/ 
Phase 2.- A clinical study of electrophoretic patterns and 
uric acid levels in all patients with malignant disease admitted 
to the Unit before and after surgery and whether receiving 
cytotoxins or not. 
Phase 3.- A clinical and laboratory study of the part 
played by the breakdown of normal tissues in determining serum 
electrophoretic and uric acid patterns following treatment with 
cytotoxic drugs. 
Each phase to occupy a period of 9 -12 months; Phases 2 and 3 
to depend in their final form on the outcome of the preceding 
phases, but to run, in part, concurrently. 
This paper is a report of the results of Phase 1 which has 
occupied the 12 -month period from April 1964 to date. At this 
stage the work remains incomplete and continues as part of the 
total study. 
Two groups of patients were studied. 
Group A - Patients with locally advanced tumours or with 
known metastases. Many of these patients had been submitted to 
operation and all received cytotoxic drugs. 
Group B - Patients with advanced inflammatory disease, 
e.g. empyema of gallbladder, ulcerative colitis, Crohnts disease. 
Group/ 
Group A patients.- These patients were mostly admitted to 
a single surgical charge over a 12 -month period, as stated above. 
Certain patients were, however, seen and treated in other units, 
and one patient remained throughout her course in a medical charge. 
Group B patients.- The control group of patients were all 
admitted to a single surgical charge over the same 12 -month 
period. They represent only a small proportion of the total 
patients admitted during this period and were studied concurrently 
with Group A patients wherever possible. 
IV INVESTIGATIONS 
In addition to the usual and routine investigations required 
by the patient's particular condition, all patients in the study 
had an initial estimation of plasma proteins, serum electrophoresis, 
and serum uric acid carried out. In 13 Group A patients and in 
6 Group B patients the urine was tested quantitatively for uric acid. 
An E.S.R. was carried out in all patients. 
Further estimations of serum electrophoresis, uric acid, 
urinary uric acid and E.S.R. were made at intervals after operation 
or after administration of cytotoxic drugs. 
The/ 
The method employed for serum electrophoresis was that 
described by Albert Recht and employed routinely in our biochemical 
laboratory Serum uric acid was determined by the modified 
method described by Eichhorn et alb and the urine uric acid was 
estimated by the method of Folin and Macallum.7 
It is considered throughout the study that changes in any 
particular pattern or level are of greater significance than 
individual levels. 
The initial results and the changing results obtained 
following cytotoxic therapy constitute the basis of this phase 
of the study. 
V CASE SUMMARIES 
(a) Treated patients 
CASE NO.- 1 INITIALS.- W.S. SEX.- M AGE.- 60 
DIAGNOSIS.- Hypernephroma right kidney. 
HISTORY.- Increasing pain in right groin for 5 months with 
intermittent haematuria. 
Large hypernephroma removed on 28/2/64. 
CYTOTOXIC TREATMENT.- Thiocolciran, 40 mg, by intravenous injection 
between 15/3/64 and 6/4/64. 
PROGRESS.- Patient remains alive and free of evidence of recurrence. 
POINTS OF INTEREST.- Typical presentation of hypernephroma. 
Cytotoxic drugs were exhibited as prophylactic measure. 
0( -2- globulin raised initially and remaining elevated throughout. 
No uric acid levels available for this patient, and urine uric 
acid estimations were not carried out. 
COMMENT.- Insufficient results for comment. Of interest because 
of raised 06-2- globulin with small tumour. 
CASE/ 
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CASE N0.- 2 INITIALS.- W.E. SEX.- M AGE.- 81 
DIAGNOSIS.- Carcinoma of stomach. 
HISTORY.- Increasing dysphagia for 6 months, complete dysphagia 
for 2 weeks. Severe dyspepsia. Marked anorexia and weight loss. 
CYTOTOXIC TREATMENT.- Thiocolciran, 350 mg, by intravenous injection, 
and methotrexate, 32.5 mg, orally in intermittent courses. 
PROGRESS.- Complete disappearance of dysphagia within 10 days of 
commencing cytotoxic therapy with gain in health and improvement in 
general condition. Relapse after 3 months. Further 3 months' 
remission with second course of treatment. Mousseau -Barbin tube 
inserted through cardia 8 months after commencing treatment. 
Died 15/1/65. 
POINTS OF INTEREST.- Advanced carcinoma of cardia, initially 
causing confusion with peptic oesophagitis and stricture formation 
because of severe pain. Good subjective response to treatment. 
04z-2-globulin slightly raised initially. Elevation becoming marked 
shortly after commencing treatment, thereafter persisting at 
increased level. Serum uric acid results for this patient are not 
available and urine uric acid estimations were not carried out. 
COMMENT.- Insufficient results are available to comment on tumour 
effect, but rising oL 2- globulin suggests continued activity despite 
subjective improvement. 
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CASE NO.- 3 INITIALS.- A.M. SEX.- M AGE.- 54 
DIAGNOSIS.- Carcinoma of stomach. 
HISTORY.- Epigastric discomfort, nausea after meals, and loss 
of 7 lb in weight over 3 months. 
Inoperable carcinoma of stomach at laparotomy on 10/3/64 
(Western General Hospital). 
CYTOTOXIC TREATMENT.- Thiocolciran, 650 mg intravenously, and 
methotrexate, 505 mg orally. Cyclophosphamide, 1200 mg 
intravenously. 
PROGRESS.- Symptomatic control for 6 months and then rapid 
decline to death in the ward on 19/11/64. Post -mortem not 
requested. 
POINTS OF INTEREST. - o4-2-globulin normal initially and remaining 
normal until 6 months after treatment commenced when the level 
was significantly elevated and remained high. Serum uric acid 
remained normal throughout and no estimation of urine uric acid. 
COMMENT.- Very doubtful if any significant effect of drugs on 
tumour breakdown although activity checked for 6 months. 
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CASE NO.- 4 INITIALS.- J.McA. SEX.- F AGE.- 61 
DIAGNOSIS.- Carcinoma of ovaries. 
HISTORY.- Invasive epidermoid carcinoma of cervix found on cone 
ciopsy April 1964. At subsequent laparotomy on 6/5/64 found to 
have extensive malignant disease of both ovaries with widespread 
peritoneal metastases. 
CYTOTOXIC TREATMENT.- Thiocolciran, 380 mg by intravenous injection; 
thiotepa, 22.5 mg intrapleurally; and cyclophosphamide, 600 mg orally. 
PROGRESS.- Remained well for 2 months, developed pleural effusion 
uncontrolled despite treatment, and deteriorated rapidly to death 
at the end of October 1964. 
POINTS OF INTEREST.- 4:4-2-globulin normal initially and remaining 
normal throughout. Serum uric acid slightly raised initially and 
remaining high -normal throughout. No estimation of urine uric acid. 
COMMENT.- Insufficient results obtained,but of interest from the 
point of view of silent tumour already advanced at diagnosis, with 
normalot 2, levels and probably no significant response to treatment. 
CASE/ 
-12- 
CASE NO.- 5 INITIALS.- M.O. SEX.- F AGE.- 45 
DIAGNOSIS.- Carcinoma of breast. 
HISTORY.- Stage III carcinoma of breast treated by radical 
mastectomy and radiotherapy in 1960. 
Found to have rheumatic heart disease in 1962 and subsequently 
developed congestive cardiac failure in July 1964. Bilateral 
pleural effusions at that time thought either due to heart condition 
or to recurrent malignant disease. 
Readmitted to medical unit January 1965 with ascites and 
massive intra- abdominal malignancy. 
CYTOTOXIC TREATMENT.- Cyclophosphamide, 1,400 mg, by intravenous 
infusion. 
POINTS OF INTEREST.- Case of especial interest because results 
available at an early stage and at a point when doubt existed as 
to nature of pleural effusions. 0( -2-globulin raised initially 
and remaining very high throughout. Serum uric acid raised 
initially and remaining high throughout. No estimation of urine 
uric acid. 




CASE NO.- 6 INITIALS.- A.P. SEX.- M AGE.- 63 
DIAGNOSIS.- Carcinoma of stomach. 
HISTORY.- Increasing lassitude, anorexia, loss of weight and 
left hypochondrial pain for 6 months. Diagnosed as inoperable 
carcinoma of stomach at laparotomy on 7/1/64. 
Subtotal gastrectomy 1 year later (20/1/65). 
CYT0T0XIC TREATMENT.- Thiocolciran, 580 mg by I.V.I. and 
methotrexate, 370 mg orally in 3 courses. Treatment continues. 
PROGRESS.- Remains well with normal appetite, steady gain in 
weight and free of symptoms. 
POINTS OF INTEREST.- Case of especial interest from point of view 
of "second -look" procedure. Gastrectomy successfully carried out 
1 year after an operative diagnosis of inoperable malignant disease 
of stomach. Serum proteins not estimated at initial operation 
(before commencing present programme). ti,.-2-globulin was raised 
at first estimation in June 1964 and remains elevated. Uric acid, 
initially high, has fallen progressively since and remains low. 
Urine uric acid estimations within normal range on occasions estimated. 
COMMENT.- Results suggest only a minimal effect on tumour breakdown 
despite apparent subjective control for a year, but activity possibly 
checked during this period. Case illustrates difficulty of estimating 
such factors as operability and clinical response to cytotoxins. 
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CASE NO.- 7 INITIALS.- J.C. SEX.- M AGE.- 58 
DIAGNOSIS.- Hypernephroma. 
HISTORY. - Right nephrectomy for an extensive hypernephroma 
13/11/62. Incomplete excision. 
Free of recurrence until 3/10/63 when reappeared with large 
mass in right loin. Mass slowly increased in size, producing 
severe local pain, with pain and paraesthesiae in right leg. 
One week's palliative radiotherapy to mass 13/5/64 with 
improvement in leg symptoms, but no effect on pain. 
CYTOTOXIC TREATMENT.- Cyclophosphamide, 7,200 mg by intravenous 
injection and orally. 
PROGRESS.- Moderate relief of abdominal pain but recurrence of 
leg symptoms. Gradual deterioration in general condition and 
died at home 25/8/64. 
POINTS OF INTEREST. - Massive recurrence of hypernephroma with 
pulmonary spread and severe pain. 0C-2-globulin raised initially 
and remaining high throughout. Serum uric acid initially high, 
falling rapidly after treatment and remaining low. Urine uric acid 
high initially, remaining high but falling after treatment. 
COMMENT.- Results suggest no appreciable effect on tumour breakdown 
but possibly some slowing of activity for a short time. 
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CASE NO.- g INITIALS. - E.H. SEX.- F AGE.- 6o 
DIAGNOSIS.- Carcinoma of ovaries. Widespread peritoneal and 
omental deposits. 
HISTORY.- Progressive, painless abdominal distension for 1 week. 
At laparotomy on 7/7/64 found to have widespread malignant disease 
from ovarian primary. 
CYTOTOXIC TREATMENT. - Cyclophosphamide, 2,600 mg intravenously 
and 300 mg intrapleurally; thiotepa, 90 mg intraperitoneal and 
60 mg intrapleural. 
PROGRESS.- Control of malignant ascites and malignant pleural 
effusion obtained. Slowly developed an Addisonian state 
suggesting malignant replacement of adrenal glands. Died at 
home 16/11/64. 
POINTS OF INTEREST.- Silent development of advanced ovarian 
malignancy. oL -2- globulin slightly raised initially. Increase 
in p4. 2- globulin more marked after treatment and level remained 
high throughout. Uric acid initially low increasing after 
therapy and remaining at high -normal levels. No urine uric acid 
estimations carried out. 
COMMENT.- These results suggest a moderate effect on tumour break- 
down with apparent control of activity for 4 months. 
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CASE NO.- 9 INITIALS.- M.H. SEX.- F AGE.- 58 
DIAGNOSIS.- Carcinoma of colon. 
HISTORY.- Right hemicolectomy for carcinoma of colon 3/12/63. 
No other metastases noted at laparotomy. 
In June 1964 developed severe pain in mid -thoracic spine; 
subsequently complained of double vision, unsteadiness of gait, 
anorexia, nausea, and weight loss. 
CYTOTOXIC TREATMENT.- Thiocolciran, 6o mg, by intravenous injection; 
and methotrexate, 10 mg, orally. 
PROGRESS.- Patient clinically demonstrating widespread metastases 
but proof of these was difficult to establish. of -2- globulin 
considerably raised and remaining raised. Uric acid normal and 
remaining normal. 
COMMENT.- Too few results but probably no effect on tumour. 
CASE NO.- 10 INITIALS.- S.O. SEX.- F AGE.- 62 
DIAGNOSIS.- Carcinoma of breast. 
HISTORY/ 
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HISTORY.- Simple mastectomy and radiotherapy for Stage II 
carcinoma right breast 1947. Frequent skin recurrences treated 
by radiotherapy or excision, 1950 -1964. 
At review 29 /7/64 complained of increasing breathlessness 
and tightness right side of chest. Large right -sided pleural 
effusion present; confirmed by cytology to be malignant. 
CYT OTOXIC TREATMENT.- Thiotepa, 45 mg, by intrapleural instillation. 
PROGRESS.- Remains well and free of symptoms. 
POINTS OF INTEREST.- Very slowly growing malignancy demonstrating 
considerable "tumour -host resistance ". of -2- globulin only very 
slightly raised, and pattern not changing with treatment. Uric 
acid normal and no increase in urinary excretion with treatment. 
COMMENT.- Suggests overall effect of treatment on tumour is 
minimal despite prolonged symptomatic control. 
CASE NO.- 11 INITIALS.- P.W. SEX.- M AGE.- 55 
DIAGNOSIS.- Carcinoma of stomach. 
HISTORY.- Gnawing epigastric pain, anorexia, and weight loss for 
3 months. 
Extensive irremoveable gastric carcinoma at laparotomy on 1/7/64. 
CYTOTOXIC/ 
CYTOTOXIC TREATMENT.- Thiocolciran, 80 mg, by I.V.I.; and 
methotrexate, 100 mg, by mouth. 
PROGRESS.- Developed severe buccal ulceration and marked bone 
marrow depression. Died at home 4/8/64. 
POINTS OF INTEREST. - Typical carcinoma of stomach, severe side 
effects of cytotoxic therapy. oC- -globulin normal initially 
and remaining so. Uric acid low initially and only slightly 
increased during treatment. No estimation of urine uric acids 
carried out. 
COMMENT.- Period of treatment too short and side effects of drugs 
too severe for assessment of tumour effect. 
CASE NO.- 12 INITIALS.- M.G. SEX.- F AGE.- 57 
DIAGNOSIS.- Astrocytoma. Grade III. 
HISTORY.- Craniotomy and subtotal excision of a malignant 
astrocytoma of right temporal parietal region on 17/7/64 following a 
3 -month history of increasing headache and progressive disorientation. 
CYTOTOXIC TREATMENT.- Epodyl, 7,500 mg, by intermittent intra- arterial 
injection/ 
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injection (right internal carotid artery); thiocolciran, 4$0 mg, 
by intermittent intravenous injection; and methotrexate, 320 mg, 
orally. 
PROGRESS.- 6 months of marked symptomatic relief with rapid 
decline and death, on 15/3/65 (Eastern General Hospital). 
POINTS OF INTEREST. - Rapidly growing cerebral tumour. o' -2- globulin 
raised initially, remaining slightly elevated throughout treatment, 
but no significant change in overall pattern. Uric acid normal 
initially, and remaining unchanged throughout. No estimation of 
urine uric acid was made. 
COMMENT.- These results suggest very little influence on tumour 
despite subjective improvement. An alternative view is that the 
total bulk of tumour, even at death, was. small. The content of 
purine derivatives in cerebral tumours is unknown and therefore 
the influence on uric acid excretion is unpredictable. 
CASE NO.- 13 INITIALS.- T.H. SEX.- M AGE.- 58 
DIAGNOSIS.- Carcinoma of stomach. 
HISTORY/ 
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HISTORY.- Progressive listlessness, anorexia, and loss of weight 
for 3 months. 
Extensive infiltrating inoperable carcinoma of stomach at 
laparotomy 12/10/64. No operative procedure. 
CYTOTOXIC TREATMENT.- Thiocolciran, 350 mg, intravenously; 
methotrexate, 390 mg, orally. 
PROGRESS.- Transient buccal ulceration. General condition remained 
poor but 3 months after commencing treatment was eating reasonably 
well and free of pain. Deteriorated rapidly and died at home 15/1/65. 
POINTS OF INTEREST.- Typical carcinoma of stomach. o42- globulin 
considerably raised initially, remaining high throughout. Uric 
acid high initially and remaining high throughout. No estimation 
of urine uric acid. 
COMMENT.- Results suggest possible objective response with continued 




CASE NO.- 14 INITIALS.- E.L. SEX.- F AGE. - 48 
DIAGNOSIS.- Carcinoma of pancreas. 
HISTORY.- Progressive listlessness, anorexia, and vomiting for 
6 months with epigastric discomfort for 3 weeks. 
Inoperable carcinoma of pancreas at laparotomy 2/12/64. 
Palliative gastro -enterostomy. 
CYTOTOXIC TREATMENT.- Cyclophosphamide, 12,550 mg, by intravenous 
injection and orally. 
PROGRESS.- Patient is alive and remains'reasonably well. Has an 
enormous mass in abdomen but claims to be entirely free of pain and 
has only occasional vomiting. 
POINTS OF IN'TEREST.- 04,2- globulin raised initially, falling to 
normal levels within 2 weeks of starting treatment and subsequently 
increasing again. Serum uric acid initially normal and remaining 
normal. Urine uric acid raised initially; slight increase 
following treatment, and subsequent fall, but remaining raised. 
COMMENT.- Very advanced tumour of head of pancreas. Difficult 
to assess significance of change in o(-2- globulin pattern. Uric 
acid levels suggest minimal influence on tumour. 
CASE/ 
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CASE NO.- 15 INITIALS.- J.K. SEX. - M AGE.- 63 
DIAGNOSIS.- Carcinoma of pancreas. 
HISTORY.- Irremoveable carcinoma of head of pancreas at laparotomy 
on 6/3/62. Cholecyst- jejunostomy. 
Reporting 17/11/64 with increasingly severe epigastric and 
back pain for 6 months associated with marked weight loss and 
severe steatorrhoea. Large mass palpable in epigastrium. 
CYTOTOXIC TREATMENT.- Cyclophosphamide, 5,650 mg, by intravenous 
infusion and orally. 
PROGRESS. - Only minimal and transient relief of pain. No effect 
on steatorrhoea. Progressive deterioration to death at home on 
12/1/65. 
POINTS OF INTEREST.- No protein or uric acid estimations are 
available for initial admission in 1962. 0(4-2- globulin significantly 
raised when reporting in November and remaining high. Uric acid 
normal and remaining so. Urine uric acid normal and not affected 
by treatment. 
COMMENT.- No objective effect on tumour. 
CASz/ 
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CASE NO.- 16 INITIALS.- J.H. SEX.- M AGE.- 59 
DIAGNOSIS.- Cerebral astrocytoma, Grade III. 
HISTORY.- Inoperable Grade III astrocytoma of right parietal 
temporal region of brain at operation on 5/11/64 (Western General 
Hospital). Following operation remained drowsy, disorientated, 
and developed an enormous bulging over the decompressed area. 
CYTOTOXIC TREATMENT.- Epodyl, 5,000 mg, by intra- arterial infusion; 
thiocolciran, 70 mg, by intravenous injection; cyclophosphamide, 
700 mg, orally; and methotrexate, 35 mg, orally. 
PROGRESS. - Rapid and remarkable improvement in general state and 
in central nervous signs, persisting for 5 weeks after treatment. 
Thereafter rapid decline to death at home at the end of January 
1965. 
POINTS OF INTEREST.- 4;4.-2- globulin raised initially and, although 
no evidence of metastases, remained high throughout. Serum uric 
acid normal and remaining normal throughout. No estimation of 
urine uric acid. 
COMMENT.- Results suggest no objective response to treatment despite 
reasonable subjective response. 
CASE/ 
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CASE N0.- 17 INITIALS.- A.G. SEX.- M AGE.- 61 
DIAGNOSIS.- Carcinoma of stomach. 
HISTORY.- Progressive anorexia, weight loss and epigastric pain 
for 9 months. Chronic asthmatic. 
Extensive inoperable carcinoma of stomach at laparotomy 
16/11/64. No operative procedure. 
CYTOTOXIC TREATMENT.- Thiocolciran, 400 mg, intravenously and 
methotrexate, 80 mg, orally. Treatment continues. 
PROGRESS. - After initial period of increased symptoms has for 
4 months been well with fair appetite, less pain, and steady weight. 
POINTS OF INTEREST.- O-2- globulin significantly raised when first 
presented, remaining high but with one record of a normal level 
three months after commencing treatment; later levels again 
elevated. It is to be noted that previous medical notes record 
a normal 04.2- globulin level despite chronic asthma. Serum uric 
acid level raised initially, remaining high. Urine uric acid high, 
remaining high after treatment. 
COMMENT.- Results suggest slight but definite effect on tumour, 
correlating with good symptomatic response. 
CASE/ 
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CASE NO.- 18 INITIAIS.- J.T. SEX.- M AGE.- 59 
DIAGNOSIS.- Carcinoma of pancreas. 
HISTORY.- Aching lower abdominal pain for 2 years, diabetes and 
steatorrhoea for 6 months. 
Inoperable carcinoma head of pancreas at laparotomy 2/12/64. 
Extensive hepatic deposits. No operative procedure. 
Palliative cholecyst -jejunostomy for obstructive jaundice 
8/2/65. 
CYTOTOXIC TREATMENT.- Cyclophosphamide, 9,400 mg, intravenously, 
orally and intraperitoneally. 
PROGRESS.- Initial dramatic relief of pain and steatorrhoea 
but of short duration. Massive increase in hepatic deposits with 
ascites. Died at home 18/4/65. 
POINTS OF INTEREST.- 0<-2-globulin raised initially, remaining 
high throughout. Serum uric acid high initially, falling after 
treatment with one peak after second operation. Levels thereafter 
falling. Urine uric acid slightly raised initially with further 
slight rise following treatment. 
COMMENT.- Results suggest no significant effect on tumour despite 
initial subjective improvement. 
CASE/ 
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CASE NO.- 19 INITIALS.- J.W. SEX.- M AGE.- 35 
DIAGNOSIS. - Widespread carcinoma of unknown origin. 
HISTORY. - 5 -month history of increasingly severe pain in right 
lower chest and abdomen. Pain undiagnosed despite prolonged 
investigation in medical unit. 
Diagnostic laparotomy 18/1/65 revealed widespread 
transperitoneal dissemination of carcinoma of unknown origin. 
Biopsy only. No operative procedure. 
CYTOTOXIC TREATMENT.- Nitrogen mustard, 30 mg, by intravenous 
injection and cyclophosphamide, 2,400 mg, orally. 
PROGRESS.- Almost complete but temporary remission of pain 
achieved with some regression of involved. glands. Overall 
progression, however, of a rapidly disseminating carcinoma of 
which the primary site was never found. Died at home 22/3/65. 
POINTS OF INTEREST.- 0(-2- globulin significantly raised initially 
and elevation becoming more marked throughout course of treatment. 
Serum uric acid level frequently estimated but never elevated. 
Urine uric acid levels slightly elevated and remaining unchanged 
throughout treatment. 
COMMENT.- Results suggest no significant effect on tumour breakdown 
or activity. 
CASE/ 
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CASE NO.- 20 INITIALS.- J.G. SEX.- F AGE.- 53 
DIAGNOSIS.- Carcinoma of pancreas. 
HISTORY.- 3 -month history of intermittent colicky abdominal pain, 
increasing constipation and general malaise. 
Inoperable carcinoma of body and tail of pancreas with extensive 
omental and peritoneal and hepatic deposits proven at laparotomy on 
14/10/64. No operative procedure carried out. 
In January 1965 presented with constant severe incapacitating 
pain in abdomen and back. Confused and hallucinated. 
CYTOTOXIC TREATMENT.- Cyclophosphamide, 1,200 mg, by intravenous 
drip over 24 hours. 
PROGRESS. - Rapid and dramatic relief of pain. Improvement in 
general condition. Able to sleep and no longer hallucinated. 
Died at home 3/3/65. 
POINTS OF INTEREST.- Typical example of a carcinoma of body and 
tail of pancreas. No estimations of proteins or uric acid at 
initial admission. 0( -2- globulin considerably raised when patient 
re- presented with severe pain. Level increased steadily following 
treatment. Uric acid low initially and remaining low throughout. 
Urine uric acid slightly raised, moderate increase following treatment 
but again dropping fairly rapidly. 
Corne/ 
28 
COMMENT.- Results suggest minimal objective tumour response 
in addition to subjective improvement. 
CASE NO.- 21 INITIALS.- M.K. SEX.- F AGE.- 52 
DIAGNOSIS.- Carcinoma of breast. 
HISTORY. - Radical mastectomy for Stage I carcinoma right breast 
August 1963. 
Excision of local recurrence mastectomy scar January 1964 and 
removal of pre -malignant adenoma of rectum. 
Further polyp excised from rectum and shown to be papillary 
carcinoma, February 1964. Further skin and axillary node 
recurrence between April and July 1964. Progressive skeletal and 
pulmonary metastases between September 1964 and January 1965. 
Skeletal metastases treated with symptomatic relief by radiotherapy. 
Increasing breathlessness and general malaise. Large right pleural 
effusion shown to be malignant on cytology. 
CYTOTOXIC TREATMENT.- Cyclophosphamide, 1,000 mg, by intrapleural 
instillation. Remains under treatment. 
PROGRESS.- Symptomatically much improved, without repeated 
aspiration. 
POIN]TS/ 
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POINTS OF INTEREST.- No record of proteins or uric acids until 
brought into this programme. 04.2- globulin normal initially and 
remaining so. Uric acid initially low, but rising to a high level 
immediately prior to treatment. Further increase following 
treatment with sustained high level. Urine uric acid initially 
normal, rising to significant peak before treatment commenced, 
falling following treatment, but remaining moderately elevated. 
COMMENT.- Patient demonstrates widespread disease with possible 
objective response to treatment. Further results required. 
CASE NO.- 22 INITIALS.- J.McI. SEX.- F AGE.- 54 
DIAGNOSIS.- Metastatic malignant disease of unknown primary origin. 
HISTORY.- Swelling in right groin for 6 weeks with increasingly 
severe pain in the region of D6. Clinically diagnosed as 
widespread malignant disease but the primary site could not be 
defined. Palliative radiotherapy to groin glands and dorsal spine, 
Dec.1964. Some relief of pain and reduction in size of glands. 
Further metastases appearing and rapid general deterioration. 
CYTOTOXIC/ 
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CYTOTOXIC TREATMENT.- Cyclophosphamide, 1,800 mg, by intravenous 
drip and intravenous injection. Treatment continues. 
PROGRESS.- Continued to run high grade pyrex_ia, but slow 
improvement in general condition. 
POINTS OF INTEREST.- Rapidly spreading malignant disease with 
considerable systemic disturbance. 0C-2- globulin raised initially 
and remained high throughout treatment. Serum uric acid initially 
low but rising to above normal immediately prior to treatment and 
again decreasing following treatment. Urine uric acid output high 
on normal ward diet, rising 48 hours after treatment and falling 
again 2 weeks after treatment commenced. 
COMMENT.- These results suggest very little effect on breakdown 
of the tumour but possibly indicate(by the falling uric acid level) 
some reduction in activity. This is, to some extent, supported 
by clinical progress. 
CASE NO.- 23 INITIALS.- R.C. SEX.- M AGE.- 66 
DIAGNOSIS.- Carcinoma of stomach. 
HISTORY.- Increasing epigastric pain with vomiting after meals 
and loss of 2 st in weight over 6 months. 
Inoperable carcinoma of stomach at laparotomy 23/3/65. 
CYTOTOXIC/ 
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CYTOTOXIC TREATMENT.- Thiocolciran, 120 mg, intravenously and 
methotrexate, 115 mg, orally. Treatment continues. 
PROGRESS.- At last review was feeling well and beginning to 
eat normally. Pain decreasing. 
POINTS OF INTEREST. - 0(-2- globulin normal initially, becoming 
elevated at last reading. Serum uric acid normal and remaining 
normal. No estimation of urine uric acid. 
COMMENT.- Too early to make proper comment, but no evidence as yet 
of objective response. 
CASE NO.- 24 INITIALS.- J.M. SEX.- M AGE.- 40 
DIAGNOSIS.- Carcinoma of bronchus. Gross hepatic metastases. 
HISTORY.- Intermittent bouts of sweating, dizziness and progressive 
weight loss for 3 months. 
Laparotomy confirmed gross hepatic metastases. 
CYTOTOXIC THERAPY.- Thiotepa, 75 mg, by intra -arterial (hepatic) 
injection. Hepato -renal failure and death on 14/4/65. 
POINTS OF INTEREST.- Although this patient was not dealt with by 
myself and only a few results are available, it is interesting to 
note/ 
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note a normal - 2_globulin despite gross liver involvement and 
a very high serum uric acid of 25.5 mg /100 ml 36 hours after 
administration of cytotoxic agent. 
COMMENT.- This level of hyperuricaemia may well have produced 
acute renal failure and suggests significant tumour breakdown. 
CASE NO.- 25 INITIALS. - E.C. SEX.- M AGE. - 71 
DIAGNOSIS.- Inoperable carcinoma of stomach. 
HISTORY.- Pain in left iliac fossa, increasing anorexia, and 
excessive oral flatulence for 2 weeks. Palliative gastro- 
enterostomy 1/3/65 for extensive carcinoma of stomach. 
CYTOTOXIC TREATMENT.- Thiocolciran, 140 mg, by I.V.I. and 
methotrexate, 230 mg, orally. Treatment continuing. 
PROGRESS.- Pain -free, eating normally, feeling well. 
POINTS OF INTEREST.- Advanced carcinoma of stomach with brief 
history. 0C -2- globulin and uric acid normal initially. Slight 
increase in 4.2- globulin 1 week after commencing therapy but no 
significant change in uric acid level. Urine uric acid raised 
initially, subsequently falling to normal levels. 
COMMENT/ 
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COMMENT.- Further records required in this case, but probably 
no objective effect on tumour. 
CASE NO.- 26 INITIALS.- A.W. SEX.- F AGE.- 63 
DIAGNOSIS.- Carcinoma of breast. Malignant pleural effusion 
and skin recurrence. 
JiISTORY.- Stage III carcinoma right breast treated by radical 
mastectomy and radiotherapy, September 1963. Excision of 
recurrent glands right axilla, June 1964. Severe herpes zoster 
left 10th nerve distribution, September 1963. 
Increasing breathlessness, tightness in left chest, and pain 
in left 10th nerve distribution for 3 weeks. Large left pleural 
effusion proved by cytology to be of malignant origin. 
CYTOTOXIC TREATMENT.- Cyclophosphamide, 1,200 mg, by intrapleural 
instillation. Treatment continues. 
PROGRESS.- Symptomatic relief from breathlessness; but left -sided 
chest pain persists. 
POINTS/ 
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POINTS OF INTEREST.- Patient with uncontrolled malignant disease 
of breast of slow progress. C -2-globulin raised initially 
(no results available for 2 years previously). Level subsequently 
recorded as normal on 2 occasions and again being raised slightly 
one month after commencing treatment. Uric acid within normal 
limits and level unchanged by treatment. No estimation of urine 
uric acid levels. 
COMMENT.- Tumour showing no evidence of objective response. 
CASE NO.- 27 INITIALS.- J.W. SEX.- M AGE.- 66 
DIAGNOSIS.- Hypernephroma, right kidney. 
HISTORY.- Four months intermittent nausea, vomiting, diarrhoea and 
loss of 1 st in weight. One episode of mild haematuria 2 weeks 
previously. 
Clinically, enormous mass in right abdomen shown radiologically 
to be an extensive hypernephroma of right kidney. 
CYTOTOXIC TREATMENT.- Cyclophosphamide, 3,600 mg, by direct 
intra- arterial infusion right kidney, and intravenous injection. 
Treatment continued. 
PROGRESS/ 
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PROGRESS. - Rapid subsidence of nausea, vomiting and diarrhoea 
with return of appetite and gain in weight. Abdominal mass 
essentially unchanged. 
POINTS OF INTEREST.- Advanced hypernephroma presenting with 
gastro -intestinal symptoms. o<-2-globulin slightly raised and 
serum uric acid considerably raised when first presented. 
0( -2- globulin and uric acid levels remaining high with small peaks 
in uric acid levels corresponding to intermittent intra- arterial 
injections. This patient demonstrated a high concentration of 
uric acid in the urine with a marked increase following the first 
exhibition of cytotoxic agent. 
COMMENT.- Suggests a possible objective as well as subjective 
response. 
CASE NO.- 28 INITIALS.- R.G. SEX.- M AGE.- 59 
DIAGNOSIS.- Carcinoma of colon. 
HISTORY.- Colicky lower abdominal pain, increasing anorexia and 
weight loss for 3 months; vomiting and diarrhoea for 2 weeks. 
Advanced carcinoma of transverse colon with involvement of 




CYTOTOXIC TREATMENT.- Thiocolciran, 210 mg, intravenously; and 
methotrexate, 190 mg, orally. Treatment continues. 
POINTS OF INTEREST. - Electrophoretic pattern normal when first 
seen and remaining so. Serum uric acid normal initially, becoming 
high -normal after initiating treatment. Urine uric acid high 
initially with slight rise following treatment. 
COMMENT.- Advanced tumour without change in protein pattern. 
Early uric acid results suggest possible tumour effect. 
CASE NO.- 29 INITIALS.- P.D. SEX.- M AGE.- 63 
DIAGNOSIS.- Carcinoma of stomach. 
HISTORY.- 8 -year history of dyspepsia considered on X -ray and 
oesophagoscopy to be due to peptic oesophagitis. 
Increasing dyspepsia for 1 week culminating in a severe 
haematemesis. 
Inoperable carcinoma of stomach at thoraco- laparotomy on 
7/4/65. 
CYTOTOXIC TREATMENT.- Thiocolciran, 90 mg, by intravenous injection; 
and methotrexate, 50 mg, orally. Treatment continues. 
PROGRESS/ 
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PROGRESS.- Eating moderately well; no pain at present. 
POINTS OF INTEREST.- Advanced carcinoma of stomach long regarded 
as peptic oesophagitis although under repeated review. Also found 
to have duodenal ulcer. O(-2- globulin slightly raised and remaining 
so to date. Uric acid normal throughout. Urine uric acid 
estimations not carried out. 
COMMENT.- Remains under treatment and requires further results. 
CASE NO.- 30 INITIALS.- J.M. SEX.- M AGE.- 61 
DIAGNOSIS.- Carcinoma of bronchus. 
HISTORY.- 3 -month history of intermittent haematuria associated 
with marked weight loss, progressive dyspnoea, listlessness and 
lethargy. Marked ankle swelling for 1 week. 
Radiotherapy for carcinoma of maxillary antrum, June 1963. 
CYTOTOXIC TREATMENT.- Cyclophosphamide, 1,400 mg, by intra -arterial 
and intravenous injection. 
PROGRESS.- Patient demonstrated widespread malignant disease with 
superimposed chest infection. Progressive decline to death on 17/4/65. 
POINTS/ 
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POINTS OF INTEREST.- Carcinoma of bronchus, probably presenting 
with secondary in maxillary antrum as first evidence and 
subsequently presenting as "a typical left -sided hypernephroma ". 
oL 2- globulin not raised at any stage. Uric acid initially normal. 
Moderate increase following initial burst of therapy, subsequently 
returning to normal levels. No estimation of urine uric acids. 
COMMENT.- Period of assessment too short but uric acid levels 
suggest a possible effect on tumour breakdown. 
(b) Control patients 
I have not considered it necessary to detail the individual 
case histories of the patients included in the control group 
(Group B). 
The disease conditions from which they suffered, the treatment 
they underwent, and the patterns of a(- 2- globulin, serum and urine 
uric acid are as detailed in Tables 8 -10. 
It is sufficient to say that the diagnosis in each case was 
established by accepted means, and in those cases in which there 





The results of the study are as detailed in Tables 1 -10 
Tables 1-7 summarise the results of the treated patients (Group A) 
and Tables 8 -10 summarise the results in the control group (Group B). 
It is considered that these tables are sufficient explanation in 
themselves but points of interest will be elaborated in the Discussion. 
VII ASSESSMENT OF RESULTS 
In assessing the results obtained a number of factors must be 
taken into consideration. 
A of 33 patients were introduced into the programme but 
of these 3 could not be assessed. In one case the patient was 
admitted at an early stage to another hospital and his progress 
could not be personally supervised. A second patient was irregular 
and infrequent in attendance and no worthwhile series of results was 
obtained. The third patient was withdrawn because of the severe 
side effects resulting from the first two days of cytotoxic treatment. 
A total of 30 patients with advanced malignancy was therefore 
studied (Group A). Within this group the overall coverage of 
results is satisfactory but in four cases, still under treatment, 
insufficient results are available, and two cases are included 
entirely/ 
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entirely on the grounds of unusual interest despite the results 
obtained being strictly inadequate. 
Thirty -one patients suffering from various forms of 
inflammatory disease were studied as controls (Group B). 
All of these cases were in- patients or at convalescent centres. 
The problem of out -patient investigation and assessment in 
the treated group proved one of considerable magnitude. Although 
many of these patients were able to continue frequent attendance, 
others were prevented from doing so by virtue of distance, lack 
of transport, or stage of disease. On occasion the patients 
were visited in nursing homes or in other units, but no attempt 
was made to employ the help of general practitioners on the basis 
that such an imposition was unjustified. 
It is important to record that the number of patients with 
advanced malignant disease treated with cytotoxins and included 
in this programme, does not represent the total number of cases 
with advanced disease seen during the course of 12 months. 
It was not considered ethical to exhibit cytotoxins in a 
certain number of cases that were already too advanced at diagnosis 
and in whom there appeared no possibility of palliation. Altogether, 
$ patients came into this category and all died in the ward or at 
home within a short time of diagnosis. 
All/ 
All patients with localised, surgically- treatable malignant 
disease have been excluded from this phase of the study. 
Since there appears to be no previous study of this kind 
the intervals of assessment following cytotoxic therapy 
(or operation) have been selected somewhat arbitrarily. 
Observations in the large group of patients referred to 
in the introduction (92 cases of malignant disease of various 
types treated with cytotoxins) suggested that any change recorded 
occurred most commonly within the first few weeks after exhibition 
of cytotoxins or within one week of operative manipulation. 
This would appear analogous to the accepted work on the metabolic 
response to injury in surgical operations. 
Estimations were therefore carried out in both groups within 
24-72 hours of starting treatment or of an operation and again 
within 4-7 days of commencing treatment or carrying out surgery. 
In the treated patients further estimations were carried out at 
intervals of 2 weeks, 1 month, 2 months, 3 months and 6 months. 
For the reasons already given above, this ideal and intended 
pattern could not be followed in every case. In a few cases, 
however, almost daily estimations were possible, and particular 
significance may be given to the results obtained in these cases. 
The/ 
- 42- 
The fact that many patients died in their homes precluded 
the possibility of carrying out autopsy in all but 4 of the 17 
cases who died during the course of the programme. In all 
treated cases, however, the diagnosis was confirmed histologically 
with the exception of one case. This patient with clinical and 
radiological evidence of a hypernephroma remains under treatment 
and no biopsy has been obtained to date. One patient, W.E. aged 81, 
was treated with cytotoxic agents for 8 months before positive 
biopsy was obtained by oesophagoscopy. It is to be further noted 
that in this patient earlier attempts at biopsy via an 
oesophagoscope had resulted in a report of inflammatory tissue only. 
Finally, it must be pointed out that it was initially planned 
to incorporate a third group of patients with non -inflammatory 
conditions, e.g. hernia, to act as normal controls. Reference to 
the literatúA e and consultations with the University biochemists, 
however, suggested that the normal values of the serum electrophoretic 
pattern and the serum uric acid were sufficiently well established 
within a laboratory complex to allow the normal values and normal 
ranges in daily use to be employed. This was obviously a very 
considerable factor in time saving but is accepted as a significant 
omission (Table 1). 
VIII DISCUSS/ 
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VIII DISCUSSION 
Significance of changes in 0e-2-globulin 
The exact origin of the plasma globulins is uncertain but 
they are believed to be widely formed in the body by the 
reticuloendothelial system, the plasma cells, and the lymphoid 
nodules. 
The o-2-globulin fraction of the serum electrophoretic 
pattern is not a single substance but a number of closely related 
proteins, including certain glyco- and lipoproteins migrating 
between albumen and p- globulins, and only separated artificially 
from «-l-globulins by electrophoresis. Nevertheless, the 
04:-.2-globulin fraction behaves sufficiently as a single unit to 
allow of assessment under the circumstances of this study. 
Very little appears to be known concerning the factors 
which affect the level of 0C-2- globulin in the plasma. The 
presence of an elevated 6( -2- globulin has been dismissed by 
certain authors as due to increased tissue necrosis in 
inflammatory and neoplastic conditions. Although this may, 
to some extent, be true it would appear likely from the results 
obtained that a raised ¿ 2- globulin is not necessarily a concomitant 
of even severe inflammatory change (with necrosis) while a raised 
level/ 
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level is a very common finding in malignant disease. It is 
tempting therefore to consider that a raised 0e-2- globulin in 
these cases is in some way related to the presence or activity 
of a malignant lesion. Whether or not the actual level of the 
0e-2- globulin is of any significance is not known. 
Brackenbridge (1964) has shown that there is a high 
correlation between (X-1 and 04,-2 globulins and between other 
fractions of the serum proteins in certain diseased but no 
definite significance is attached to changes in protein pattern. 
Although the-2 fraction was raised in 22 of the 30 cases 
studied (73 %) the findings of a raised level in 8 of the 31 
control patients (25;ö) with inflammatory disease confirms 
this is not a finding specific to malignant disease1° It must be 
accepted that the p4,-2-globulin fraction is probably raised in a 
variety of disease conditions, but I do not concede to Petermannts 
view that the finding of a raised k2-globulin level is of no 
11 
diagnostic significance in malignant disease. 
An elevation in the level of W,2-globulin occurs with 
sufficient frequency to at least warrant the suspicion of 
malignancy in many cases, and particularly where other signs of 
inflammation are absent. A raised level is probably also of 
some value in the diagnosis of metastatic spread at a stage before 
this becomes clinically manifest. 
T hei 
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The concept of cancer as a systemic disease from the outset 
is accepted and the frequency with which changes occur in a 
metabolic field such as represented by the 6( -2- globulin gives 
further support to this view. It is suggested that a raised 
0C- 2- globulin in malignant disease may represent a feature of 
tumour -host relationship and occur as a reaction to the presence 
of a neoplasm. 
The value of a raised04--2- globulin level as a prognostic 
guide in the treatment of malignant disease is a problem requiring 
particular thought. If a high initial level is accepted as in 
some way related to the presence or activity of a malignant lesion 
then a persistently high level, despite treatment would suggest 
continued activity of the neoplasm. A normal level initially and 
a level remaining normal throughout is more difficult to interpret. 
A possible interpretation is that the tumour activity in these 
cases is extremely slow, the breakdown of tumour is minimal and 
that the tumour -host resistance is undisturbed. 
If the level of i< 2- globulin is initially high and falls 
following treatment it suggests diminishing activity and breakdown 
of tumour and possibly a correction of the disturbed tumour -host 
relationship. An initial low level which subsequently rises 
would on this basis suggest increased activity of the tumour or 
recrudescence of a previously controlled tumour. 
It/ 
It is interesting to note that in the 10 cases demonstrating 
objective response as judged by changes in the 04.2- globulin and 
uric acid levels the above pattern is approximately followed. 
In those cases in which a prolonged subjective response occurs, 
e.g. E.L., Case no. 14, the k2-globulin level falls in parallel. 
with the subjective response. This, I regard, as further evidence 
of the o-2-globulin level reflecting a more intimate relationship 
between host tissues and tumour than has previously been accepted 
and evidence against the belief that a raised oL 2 level simply 
implies necrosis. Under these circumstances necrosis should be 
maximal with maximal effect of the cytotoxic drug. 
I would therefore regard the significance of the t 2 level 
in the assessment of response to cytotoxic drug to lie in the 
reflection of altered tumour activity and to be less important 
in assessment of tumour breakdown. 
Significance of changes in uric acid levels in blood and urine 
Uric acid derives normally from the breakdown of purine 
bases in the liver. Uric acid is a normal constituent of the 
plasma in a level of 3.7 mg /100 ml with a range of 1.5-5 mg /100 ml 
in our laboratories. It is excreted by the kidneys and appears 
in the urine in a concentration of 100 -500 mg /day on a normal diet 
but/ 
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but may rise to levels of 2,000 mg /day with a diet containing a 
high amount of purine. It is estimated that the normal ward 
diet contains only a moderate amount of purine and the normal 
range of uric acid excretion of in- patients has been calculated 
to lie within the range 100 -750 mg /day. 
Higher concentrations of uric acid in the blood and urine 
are found in gout, uraemia and leukaemia. In the absence of 
gout, uraemia or active liver disease any increase in uric acid 
levels in the plasma or urine may reasonable be assumed to reflect 
excessive purine breakdown in malignant or inflammatory tissue. 
An elevation in the level of uric acid in the plasma or 
urine may follow the administration of cytotoxic drugs or 
operative manipulation. This may be regarded as further indirect 
evidence of tumour or tissue breakdown. Any changes in the 
urine uric acid excretion would be expected to approximately 
parallel changes in the plasma levels. In the cases in which it 
has been possible to estimate urine uric acid levels this has been 
found to be so. The cases in which this estimation was carried 
out, however, are too few to allow of significant conclusions. 
One interesting point which has emerged from this study of 
uric acid levels in malignant disease, following cytotoxic therapy, 
is the possible relationship between malignant disease and gout. 
The/ 
The link appears to be in the breakdown of purine bases to form 
uric acid with resultant severe pain. Thus, the pain of gout 
is one of its particular features. This pain may be dramatically 
relieved by an antimitotic agent, colchicine, which inhibits purine 
synthesis. Colchicine is known to have some activity against 
tumour tissues. Recently we have employed the substance 
thiocolciran, a combination of an ethenylamine and colchicine, 
which has been shown to have a marked anti -tumour activity; One 
of the striking features of the use of this drug is the severe 
pain which the patient experiences at the site of tumour within 
3 -5 hours of the injection of even a small dose of the drug. 
On occasions, the pain has been sufficiently severe to require the 
use of pethidine and its time relationships are almost predictable. 
It can equally be shown that certain of these patients demonstrating 
post- injection pain have a raised uric acid initially or a rise in 
the uric acid levels in plasma and urine following administration 
of this drug. It is possible therefore that the mobilisation of 
uric acid is in some way responsible for the pain in this tumour 
as it probably is in gout. 
Remarkably little is known concerning the factors responsible 
for fluctuations in uric acid in human blood. There is little 
doubt, however, that a raised level reflects breakdown of tissue 
and it is my impression from this study that the uric acid levels 
are a better guide to the breakdown of tumour tissue than the 
0(-2-globulin/ 
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04-2- globulin levels which are perhaps more important in 
ascertaining activity of tumours. 
As with0 .2- globulin, four main patterns are evident in the 
serum uric acid levels in both treated and control patients 
(see Table 9 ). A level which is normal initially and remains 
normal throughout is presumed to imply minimal tumour breakdown 
level 
and no appreciable effect of the drug. A high initial /which 
remains high throughout treatment is accepted as evidence of 
active tumour breakdown,occurring independently of treatment, with 
probably only minimal increase in breakdown when drugs are exhibited. 
An initially normal level, which rises following treatment,is assumed 
to imply breakdown of tumour tissue as a result of the drug. 
A raised level initially which falls following treatment possibly 
implies reduced breakdown by the body, no appreciable effect on 
breakdown from the drugs, but is consistent with slowing of activity 
of the tumour. 
The fact that uric acid levels were elevated in the plasma of 
4 of 31 control patients and in the urine of 1 of the 6 control 
patients in whom this estimation was carried out, is accepted as 
evidence of considerable and rapid tissue destruction. It is 
important to note that in 2 cases demonstrating a high uric acid 
level in the plasma there was a severe degree of liver infection 
and one of these cases demonstrated a frank liver abscess. 
Effect/ 
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Effect of hepatic metastases on levels of 
0C- 2- globulin and uric acid 
It may be argued that changing levels of-2-globulin or uric 
acid in cases of malignant disease before or after treatment merely 
reflect the presence and extent of hepatic metastases. 
Nine cases in this study were known or suspected to have 
hepatic metastases. It can be seen from the analyses of these 
9 cases, as detailed in Table 6, that no definite relationship exists 
between the presence of metastases and changes in the levels of 
54-2- globulin or uric acid. Furthermore, in 17 patients 
demonstrating altered levels of 54-2- globulin and /or serum uric 
acid, there was no evidence of hepatic metastases. 
Objective assessment of tumour response at an 
early stage in treatment 
The usual and accepted means of determining tumour response 
leave much to be desired. Subjective response, as judged by 
decrease in pain, improved wellbeing, increase in appetite or 
weight, may not be paralleled by objective reduction in tumour 
size or activity. Subjective improvement is often delayed in 
its appearance and indeed may not appear before the patient has 
suffered considerable discomfort from the side effects of 
cytotoxic therapy (or radiotherapy), which subsequently proves to 
be of very little benefit. Symptomatic improvement is also 
subject/ 
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subject to considerable bias both on the part of the patient and 
on that of his medical attendant; any improvement obtained may be 
entirely unrelated to the treatment. The serial measurement of 
changes in tumour size by X -ray examination is seldom exact and 
in the several cases in which we have employed this technique the 
interpretation of the X -ray findings has been extremely difficult. 
Assessment of response to treatment by frequent observation 
of a tumour, as, for example, by means of a sigmoidoscope or 
gastroscope, is so inaccurate, even in the hands of a single 
observer, that its employment is seldom worthwhile. 
Since many of the cytotoxic drugs employed are exceedingly 
severe in their effects on normal tissues and potentially lethal 
if employed for too long or in too great a dose, the value of an 
accurate objective measurement of effect at an early stage in 
treatment is obvious. If it were possible to say early in the 
course of treatment that a particular drug was or was not being 
effective then a potentially costly and hazardous treatment could 
be stopped if no response was evident, or continued if the early 
results were favourable. 
It is seen from Table 5 that in 8 cases showing objective 
response, as judged by the OC._2_ globulin and the uric acid levels, 
there is a close correlation with subjective response. Further, 
this response was evident in 7 of the 8 cases within 2 weeks of 
starting treatment. 
without/ 
In no case showing subjective improvement 
4,!.."5571 . d'' 
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without objective evidence of response, as judged by changing 
levels of 0C-2-globulin or uric acid, was the improvement 
maintained for more than a few weeks. Conversely, 5 of the 6 
cases showing prolonged symptomatic relief demonstrated objective 
response at some stage in their treatment. Four cases demonstrating 
an objective improvement, as judged by changing levels of 
0 -2- globulin and uric acid died within 2 months of commencing 
treatment and are therefore excluded from the group showing 
subjective and objective improvement. In 2 of these 4 cases 
definite symptomatic improvement did. occur but was short -lived. 
One patient demonstrated severe side effects of treatment and 
this probably contributed to his early death. One patient 
remained ill throughout with severe intercurrent infection. 
Although the numbers involved are small and the total period 
of the study short, it is my impression that the serial estimation 
of uric acid levels in plasma and blood is of considerable value 
in assessing response to cytotoxic treatment, at least in a 
selected group of patients with advanced malignant disease. 
Furthermore, this assessment can be made in the majority of cases 
within 2 weeks of starting treatment, while the final results accord 
closely with the experience of other workers on the overall results 
of treating advanced cancer with cytotoxic drugs. 
IX SUMMARY/ 
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IX SUMMARY 
TheK -2- globulin fraction of the serum electrophoretic 
pattern, the serum uric acid level and the urine uric acid 
level were estimated in a group of 30 patients (Group A) 
demonstrating advanced malignant disease before, and at intervals 
after treatment with cytotoxic drugs. The same factors were 
estimated in a group of 31 control patients (Group B) demonstrating 
significant degrees of inflammatory disease before and at intervals 
after operation. 
The results obtained in this study are detailed and their 
possible significance discussed. 
The A6.2-globulin fraction of the serum electrophoretic 
pattern was initially raised in 22 of the 30 patients (73iß) 
with locally advanced or metastatic malignant disease and 
compared with an elevated level in 8 of 31 cases (25 %) demonstrating 
severe inflammatory disease. Although a non -specific finding in 
malignant disease the occurrence of a raised level should 
arouse suspicion in a difficult or doubtful case and may be an 
early guide to the presence of overt metastases or to their 
development. 
It is considered that the C4-2-globulin level is a possible 
guide to tumour activity following treatment with cytotoxic drugs. 
Serum/ 
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Serum uric acid levels were initially raised in 10 of the 
30 treated patients (Group A) as compared with 4 of 31 cases in 
the control group (Group B). The urine uric acid was elevated 
initially in 4 of the 13 treated patients in which this estimation 
was carried out but in only 1 of the 6 control patients. Changing 
levels of uric acid in the serum occurred in g of the 30 patients 
in Group A, following cytotoxic treatment, and in only 1 of the 31 
patients in Group B following surgical manipulation. Changes in 
the urine uric acid level in the treated group occurred on 5 
occasions in the 13 patients studied and again on 1 occasion in 
the 6 estimations among the control group. 
The number of estimations of urine uric acid are insufficient 
to draw any significant conclusions. 
It is considered that the changes in the serum uric acid 
following cytotoxic treatment of advanced malignant disease may 
be a valuable objective means of assessing tumour response. 
Furthermore, this assessment may be made within 2 weeks of 
commencing treatment in those cases in which a response is likely 
to occur. 
The assessment of objective tumour response, as determined by 
a combined study of 04,2-globulin and serum uric acid levels 
following cytotoxic therapy, produces close correlation with the 
subsequent/ 
- 55 - 
subsequent clinical course of the treated patients and significant 
subjective improvement is unlikely to occur without corresponding 
changes in these levels. 
Serial estimation of these levels as a routine following the 
employment of cytotoxic drugs may, therefore, be a valuable means of 
assessing the likely outcome of treatment and will determine,at an 
early stage,the small percentage of patients with solid tumours 
likely to be improved by continued treatment. 
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TABLE 1 




Albumin 04-1-globulin 04-2- g lobulin F-g lobulin 8-globulin 
1 7.14 ± 0.33 3.65 ± 0.31 0.421 0.10 0.67 ± 0.12 0.91 ± 0.13 1.53 ± 0.18 
2 - 51.6%68.1% 1.4% -3.3% 6.3,1-13.7% 8%-16% 9.5% -21.9% 
1 = after Sunderman 1964 : results = mean - standard deviation. 
2 = after Albert Recht 1959 : results = "x" + 2 x standard deviation. 
Serum uric acid 
Mean value = 3.7 mg /100 ml t 
Range = 1.0-5 mg /100 rat 
Urine uric acid 
100 -500. mg /24 hours : normal diet 1 
100 -2,000 mg /24 hours : high purine diet 1 
100 -750 mg /24 hours : calculated ward diet 
after Jamieson and Kay, 1965. 
TABLE 2 
GROUP A: TREATED PATIENTS 
Nature of disease No. of cases 
Cerebral astrocytoma 2 
Carcinoma of breast 4 
Il " bronchus 2 
" " colon 2 
It 
" kidney 3 
" " ovaries 
II " pancreas 4 
n 
" stomach 9 




Agent Abbreviation No. 
of cases 
in which used 
Cyclophosphamide C.P. 16 
Epodyl E 2 
Methotrexate M 13 
Nitrogen mustard HN2 1 
Thiocolciran T.C. 15 
Thiotepa T.T. 4 
N.B. (1) 12 patients were treated with one 
agent only. 
(2) 18 patients were treated with two or 
more agents, separately or in 
combination. 
TABLE 4 
GROUP A: TREATED PATIENTS 
% -2- globulin. and uric acid levels 
0(- 2- globulin Serum uric acid Urine uric acid 
No. % No. % No. 
Normal initially 8 27 20 67 9 70 
Raised initially 22 73 10 33 4 30 
Remaining normal 5 17 17 57 4 30 
Remaining raised 17 57 6 20 3 23 
Changing patterns 8 27 7 23 6 47 
N.B. Urine uric acid levels determined in 13 cases only. 
TABLE 5 
GROUP A PATIENTS: RESPONSE TO TREAT) NT 




Subjective response only 5 17 
Objective response only 4 13 
Objective and subjective response 8 27 
No appreciable response 
(or period of assessment too short) 
13 43 
(a) Subjective response 
(b) Objective response 
(c) Objective and subjective 
response 
. symptomatic improvement maintained 
for minimum period of 8 weeks. 
. definite changes 11W-2-globulin 
and /or uric acid levels at some 
stage during treatment. 
. combination of (a) and (b) above. 
(d) No appreciable response . no symptomatic improvement or 
improvement maintained for less 
than 8 weeks. 
: no change or minimal change in 
k'-2- globulin and/or uric acid levels 
during treatment. 
: too short a period of assessment. 
TABLE 6 
ROUP A : TREATED PATIENTS : 30 
EFFECT OF HEPATIC METASTASES ON LEVELS OF 
. 
-2- GLOBULIN AND URIC ACID 
No. with hepatic metastases 
No. demonstrating changes in 
oG-2- globulin level 





No. demonstrating changes in both 
04,2-globulin and serum uric acid level = 4 
No. demonstrating no change = 3 
N.B. In 17 patients demonstrating changes in 
oC 2- globulin and /or serum uric acid levels 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































GROUP B. : CONTROL PATIENTS 
NATURE OF DISEASE 
Nature of disease 
Biliary tract disease 


















GROUP B. : CONTROL PATIENTS - 31 patients 
0C-2- GLOBULIN AND URIC ACID LEVELS 
2- globulin Serum uric acid Urine uric acid 
No. % No. % No. % 
Normal initially 23 75 24 85 5 - 
Raised initially 8 25 5 15 1 - 
Remaining normal 20 66 24 85 5 - 
Remaining raised 7 22 4 12 - - 
Changing patterns 4 12 1 3 1 - 
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